The IPO provides Attovia with a substantial capital infusion, removing near-term funding risk. The next major catalyst is the full Phase 1b data readout for ATTO-1310 expected in Q4 2026/Q1 2027, which will test whether the promising early itch relief data holds in a larger, blinded dataset. Monitor for analyst initiation reports and early trading volume to gauge market reception.
Executive Summary
Attovia Therapeutics priced its 17M-share IPO at $17.00/share, raising ~$289M in gross proceeds ($265.1M net). The clinical-stage biopharma is advancing ATTOBODY-based candidates for immune-mediated diseases, with lead candidate ATTO-1310 showing promising Phase 1b itch relief data. Net proceeds will fund Phase 2 trials for ATTO-1310 and ATTO-2306 plus early pipeline work, extending cash runway into 2029.
Key Financial Metrics
Key Facts
- IPO of 17,000,000 shares at $17.00 per share, raising $289,000,000 in gross proceeds
- Underwriters have 30-day option to purchase up to 2,550,000 additional shares
- Net proceeds estimated at ~$265.1 million ($305.4 million if over-allotment exercised)
- Proceeds to fund ATTO-1310 Phase 2 ($110-130M), ATTO-2306 Phase 2 ($60-80M), and pipeline/working capital
- Post-IPO shares outstanding: 43,029,017 (45,579,017 if over-allotment exercised)
- Cash, cash equivalents and marketable securities of $132.6 million as of March 31, 2026
- Accumulated deficit of $129.7 million as of March 31, 2026; net loss of $18.7 million in Q1 2026
- Common stock approved for listing on Nasdaq Global Market under symbol ATTO
- Lock-up agreements of 180 days for officers, directors, and existing stockholders
- New investors in offering will own 39.5% of post-IPO shares but contribute 53.0% of total consideration
Financial Impact
IPO raises ~$289M gross (net $265.1M), providing capital to fund operations into 2029. Pro forma as adjusted cash, cash equivalents and marketable securities of $399.0 million.
Risk Factors
- Clinical-stage company with no approved products or revenue; high development risk
- Positive Phase 1b data may not replicate in larger Phase 2 trials
- Substantial additional capital will be needed beyond 2029 to complete development and commercialization
- Competitive market for AD and pruritus treatments with established players (Sanofi, Regeneron, Eli Lilly)
- Dependence on third-party manufacturers and CROs, including potential BIOSECURE Act exposure with WuXi
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-334997 |
| Document: 0001193125-26-334997-index-headers.html | 0001193125-26-334997 |
| Document: 0001193125-26-334997-index.html | 0001193125-26-334997 |
| Document: 0001193125-26-334997.txt | 0001193125-26-334997 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Oct 8, 2026 17d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Sep 28, 2026 28d ago | Press Release | $18.16 | awaiting T+20 | — | $13.88 (−23.57%) |
Sep 2, 2026 7w ago | Press Release | $24.20 $17.14 | ▼ −29.17% | ▼ −28.06% | $13.88 (−42.64%) |
Aug 28, 2026 8w ago | 144 / CLUSTER | $21.40 $18.16 | ▼ −15.14% | ▼ −14.95% | $13.88 (−35.14%) |
Aug 13, 2026 10w ago | Insider Buy | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 13, 2026 10w ago | Insider Cluster | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.65 $22.86 | ▲ +22.57% | ▲ +23.63% | $13.88 (−25.58%) |
Aug 7, 2026 11w ago | Insider Cluster | $19.84 $23.66 | ▲ +19.25% | ▲ +20.17% | $13.88 (−30.04%) |
Aug 7, 2026 11w ago | Insider Cluster | $20.17 $25.55 | ▲ +26.67% | ▲ +27.07% | $13.88 (−31.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers